A new method of contraception that men can use has just passed a major test and is on its way to becoming a viable commercial birth-control method. It involves the injection of a substance that can control the amount of sperm that males can produce. This provides men with a permanent solution that beats what wearing a condom or undergoing vasectomy can offer. What’s more, it’s entirely reversible.
Right now, men only have a few options with regards to contraception, Futurism notes. Either they wear condoms or get a vasectomy. Of course, there’s always the option of abstinence, but that’s not really a viable solution for most males. This is why Vasalgel is such a huge deal because it involves a single injection that can remove a substantial amount of pressure that people feel every day.
The threat of pregnancy can have a severe impact on several aspects of people’s lives. Studies have shown how societies with limited options in birth control are more likely to experience poverty, shorter life-spans, and an increased vulnerability to diseases. There’s also the matter of crippling anxiety and depression that often accompanies unexpected or unintended pregnancies, which teens represent a considerable percentage of.
So, how does Valagel work? According to the Parsemus Foundation’s website where the contraceptive’s page is hosted, it’s basically like putting a filter in the tube where sperms swim through in order to limit how much of the little tadpoles can get past.
“The procedure is similar to a no-scalpel vasectomy, except a gel is injected into the vas deferens (the tube the sperm swim through), rather than cutting the vas (as is done in vasectomy),” the site’s description reads. “If a man wishes to restore flow of sperm, whether after months or years, the polymer is flushed out of the vas with another injection.”


FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
Tabletop particle accelerator could transform medicine and materials science
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028
Trump Administration Releases New UFO Files and Apollo Mission Records
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 



